A Phase 3 interventional study of Ocrelizumab (US) and Ocrelizumab (EU) in Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Amgen. Active, not recruiting at 109 sites in 22 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States — 26 open to participants now, 44 under way, 7 of them phase 3. Multiple Sclerosis, Relapsing-Remitting · United States.
Among the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, this one is the 57th largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2025, is one of 51 in phase 3, reaches primary completion later than 23 of the 43 other live ones, and was the 212th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →26 of the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Maryland, Baltimore · Sites in United States
Ages 18–65
SetPoint Medical Corporation · Sites in United States
Ages 22–60
Georgia State University · Sites in United States
Ages 45–89
University of Florida · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 44 · Phase 3 51 · Phase 4 20
First in 1994; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 152 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 65 across the 175 interventional studies, 49 across the 53 observational. Of the 164 that completed or were terminated, 82 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 229 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 167 (68%) have results posted.
Amgen has 1 study filed under Multiple Sclerosis, Relapsing-Remitting — fewer than ten, so there is no comparison to draw.
13 of the studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05201638Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT06700343Phase 3AmgenComparison Between ABP 692 and Ocrevus® (Ocrelizumab) | 2027-04-19 |
| NCT03958877Phase 3BiogenA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis | 2027-05-20 |
| NCT07355387University of Illinois at ChicagoHome Based Functional Balance Intervention for Multiple Sclerosis | 2026-11-24 |
| NCT04768777University of Alabama at BirminghamBehavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis | 2026-12-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 229 studies in Multiple Sclerosis, Relapsing-Remitting with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants affected by relapsing-remitting multiple sclerosis (RRMS) will receive an initial dose of 300 mg ABP 692 intravenous (IV) infusion on Day 1, followed by a second dose of 300 mg ABP 692 IV infusion on Day 15. A subsequent dose of 600 mg ABP 692 IV infusion will be administered 24 weeks after the initial dose.
Drug: ABP 692
Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (US) IV infusion on Day 1, followed by a second dose of 300 mg Ocrelizumab (US) IV infusion on Day 15. At Week 24, the treatment will switch to a 600 mg IV infusion of ABP 692.
Drug: Ocrelizumab (US) · Drug: ABP 692
Participants affected by RRMS will receive an initial dose of 300 mg Ocrelizumab (EU) IV infusion on Day 1, followed by a 300 mg Ocrelizumab (EU) IV infusion on Day 15. At Week 24, participants will receive a dose of 600 mg Ocrelizumab (EU) IV infusion.
Drug: Ocrelizumab (EU)
IV infusion
IV infusion
IV infusion
Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP)
Time frame: Day 1 to Day 15
AUC From Time 0 Extrapolated toInfinity (AUC0-inf) of the Entire Initial Dose of IP
Time frame: Day 1 to Week 16
Maximum Concentration (Cmax) Following Infusion 1 of the Initial Dose of IP at Day 1 (Cmax, d1)
Time frame: Day 1 to Day 15
Cmax Following Infusion 2 of theInitial Dose of IP at Day 15 (Cmax,d15)
Time frame: Day 15 to Week 16
AUC of the Initial Dose From Time 0 to Week 16 (AUC0-wk16) of IP
Time frame: Day 1 to Week 16
AUC of Infusion 2 of IP From Day 15 to Week 16 (AUCd15-wk16)
Time frame: Day 15- Week 16
Time at Which Cmax, d1 (Tmax, d1) of IP is Observed
Time frame: Day 1 to Day 15
Time at Which Cmax, d15 (Tmax, d15) of IP is Observed
Time frame: Day 15 to Week 16
Trough Concentration (Ctrough) of IP at Day 15
Time frame: Day 15
Clearance (CL) of IP
Time frame: Day 1 to Week 16
Volume of Distribution (Vd) of IP
Time frame: Day 1 to Week 16
Terminal Elimination Half-life (T1/2) of IP
Time frame: Day 1 to Week 16
Mean Residence Time (MRT) of IP
Time frame: Day 1 to Week 16
Total number of new gadolinium enhancing (GdE) T1-weighted lesions at week 12 and week 24
Time frame: Up to Week 24
Total number of GdE T1-weighted lesions at week 12 and week 24
Time frame: Up to Week 24
Total Number of New or Enlarging T2 Hyperintense Lesion at Week 12 and week 24
Time frame: Up to Week 24
Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 24
Time frame: At Week 24
Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 24
Time frame: At Week 24
Percentage of Participants Achieving < 5 CD19+ B-cells/μL in Peripheral Blood at Week 48
Time frame: At Week 48
Percentage of Participants Achieving < 10 CD19+ B-cells/μL in Peripheral Blood at Week 48
Time frame: At Week 48
Percentage of Participants who are Relapse-free at Week 24
Time frame: At Week 24
Percentage of Participants who are Relapse-free at Week 48
Time frame: At Week 48
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a treatment, combination product, medical device, or procedure. A TEAE is defined as an AE that starts or worsens on or after the first IP infusion up to the end of study visit.
Time frame: Up to Week 72
Number of Participants Experiencing Treatment-emergent Serious Adverse Events (TESAEs)
Time frame: Up to Week 72
Number of Participants Experiencing Treatment-emergent Events of Interest (EOIs)
Time frame: Up to Week 72
Percentage of Participants with Anti-drug Antibodies (ADAs)
Time frame: Up to Week 48
Showing the first 100 of 109 sites across 22 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Started Jan 2025 (actual). Primary completion is estimated for Apr 2027, 27 months after the start.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's planned 27 months is below that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Multiple Sclerosis, Relapsing-Remitting →